...
search icon
dsgn-img

Design Therapeutics Inc Share Price

DSGN
NSQ
$10.01
-$0.04
(-0.4%)
1D
Industry: Biotechnology Sector: Health Care

Design Therapeutics Inc Analyst Forecast

Design Therapeutics Inc Share Price Chart

Design Therapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$572.49M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
96.75K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.64
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.6 L
$10.97 H
$10.01

About Design Therapeutics Inc, Common Stock

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California. more

Industry: BiotechnologySector: Health Care

Design Therapeutics Inc Stock Returns

Time FrameDSGNSectorS&P500
1-Week Return1.01%0.75%0.54%
1-Month Return10.2%-0.88%-2.01%
3-Month Return32.06%2.08%-0.28%
6-Month Return101.81%18.91%6.04%
1-Year Return173.1%6.98%12.92%
3-Year Return45.65%16.78%65.15%
5-Year Return-75.78%33.02%73.52%

Design Therapeutics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue226.00----[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue5.00K129.00K466.00K537.00K596.00K[{"date":"2020-12-31","value":0.84,"profit":true},{"date":"2021-12-31","value":21.64,"profit":true},{"date":"2022-12-31","value":78.19,"profit":true},{"date":"2023-12-31","value":90.1,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit(5.00K)(129.00K)(466.00K)(537.00K)(596.00K)[{"date":"2020-12-31","value":-500000,"profit":false},{"date":"2021-12-31","value":-12900000,"profit":false},{"date":"2022-12-31","value":-46600000,"profit":false},{"date":"2023-12-31","value":-53700000,"profit":false},{"date":"2024-12-31","value":-59600000,"profit":false}]
Gross Margin(2212.39%)----[{"date":"2020-12-31","value":-2212.39,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses8.55M35.83M67.59M77.65M61.79M[{"date":"2020-12-31","value":11.01,"profit":true},{"date":"2021-12-31","value":46.14,"profit":true},{"date":"2022-12-31","value":87.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":79.57,"profit":true}]
Operating Income(8.56M)(35.83M)(67.59M)(78.19M)(62.38M)[{"date":"2020-12-31","value":-855600000,"profit":false},{"date":"2021-12-31","value":-3583100000,"profit":false},{"date":"2022-12-31","value":-6759300000,"profit":false},{"date":"2023-12-31","value":-7819000000,"profit":false},{"date":"2024-12-31","value":-6238300000,"profit":false}]
Total Non-Operating Income/Expense---22.66M25.59M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":88.53,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(8.28M)(35.53M)(63.31M)(66.86M)(49.59M)[{"date":"2020-12-31","value":-828000000,"profit":false},{"date":"2021-12-31","value":-3553300000,"profit":false},{"date":"2022-12-31","value":-6330800000,"profit":false},{"date":"2023-12-31","value":-6686200000,"profit":false},{"date":"2024-12-31","value":-4958800000,"profit":false}]
Income Taxes(201.30K)(107.56K)(4.69M)(1.00)-[{"date":"2020-12-31","value":-20129700,"profit":false},{"date":"2021-12-31","value":-10755800,"profit":false},{"date":"2022-12-31","value":-469100000,"profit":false},{"date":"2023-12-31","value":-100,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes---(66.86M)-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-6686199900,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(8.28M)(35.53M)(63.31M)(72.36M)(49.59M)[{"date":"2020-12-31","value":-828000000,"profit":false},{"date":"2021-12-31","value":-3553300000,"profit":false},{"date":"2022-12-31","value":-6330800000,"profit":false},{"date":"2023-12-31","value":-7236000000,"profit":false},{"date":"2024-12-31","value":-4958800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(8.28M)(35.53M)(58.62M)(66.86M)(49.59M)[{"date":"2020-12-31","value":-828000000,"profit":false},{"date":"2021-12-31","value":-3553300000,"profit":false},{"date":"2022-12-31","value":-5861700000,"profit":false},{"date":"2023-12-31","value":-6686200000,"profit":false},{"date":"2024-12-31","value":-4958800000,"profit":false}]
EPS (Diluted)-(0.86)(1.14)(1.20)(0.88)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-86,"profit":false},{"date":"2022-12-31","value":-114,"profit":false},{"date":"2023-12-31","value":-120,"profit":false},{"date":"2024-12-31","value":-88,"profit":false}]

Design Therapeutics Inc Ratios

Design Therapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

DSGN
Cash Ratio 18.43
Current Ratio 18.71

Design Therapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

DSGN
ROA (LTM) -20.49%
ROE (LTM) -29.83%

Design Therapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

DSGN
Debt Ratio Lower is generally better. Negative is bad. 0.06
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.94

Design Therapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

DSGN
Trailing PE NM
Forward PE NM
P/S (TTM) 22642.01
P/B 2.95
Price/FCF NM
EV/R 11004.35
EV/Ebitda NM

FAQs

What is Design Therapeutics Inc share price today?

Design Therapeutics Inc (DSGN) share price today is $10.01

Can Indians buy Design Therapeutics Inc shares?

Yes, Indians can buy shares of Design Therapeutics Inc (DSGN) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DSGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Design Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Design Therapeutics Inc (DSGN) via the Vested app. You can start investing in Design Therapeutics Inc (DSGN) with a minimum investment of $1.

How to invest in Design Therapeutics Inc shares from India?

You can invest in shares of Design Therapeutics Inc (DSGN) via Vested in three simple steps:

  • Click on Sign Up or Invest in DSGN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Design Therapeutics Inc shares
What is Design Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Design Therapeutics Inc (DSGN) is $10.97. The 52-week low price of Design Therapeutics Inc (DSGN) is $2.6.

What is Design Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Design Therapeutics Inc (DSGN) is

What is Design Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Design Therapeutics Inc (DSGN) is 2.95

What is Design Therapeutics Inc dividend yield?

The dividend yield of Design Therapeutics Inc (DSGN) is 0.00%

What is the Market Cap of Design Therapeutics Inc?

The market capitalization of Design Therapeutics Inc (DSGN) is $572.49M

What is Design Therapeutics Inc's stock symbol?

The stock symbol (or ticker) of Design Therapeutics Inc is DSGN

How Can Investors Use Design Therapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Design Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Design Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Design Therapeutics Inc shares for Indian investors?

When investing in Design Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Design Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Design Therapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Design Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Design Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top